Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Nov 16 | 2020FDA Accepts IND for Lilly/Dicerna Cardiometabolic Asset; Gilead/Novo Announce Ph2 PoC NASH Results; Biocorp Launches Mallya in Europe; Nemaura Q3 '20 Earnings Update; Diabeloop Partners for AID System in JapanPurchase Blast
$599
Posted in: Other Nov 13 | 2020Omecamtiv Misses on Primary Outcome Components, Hits on LVEF <28% Subgroup; GALACTIC-HF @ AHA 2020Purchase Blast
$599
Posted in: Glucagon, Glucose Monitoring Nov 12 | 2020Zealand and Dario Q3 '20 Earnings Updates; Tidepool Completes Loop Human Factors Validation StudyPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery Nov 12 | 2020Medtronic Launches InPen with Integrated Guardian ConnectPurchase Blast
$599
Posted in: Glucagon, Other, SGLT2i Nov 09 | 2020EMPEROR-Reduced Filed with EMA; November 2020 CHMP Agenda; Bayer Submits Finerenone to FDA and EMA; Xeris Q3 '20 Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin Nov 09 | 2020Oramed Ph3 Oral Insulin Program Initiated; Filing Timeline UnclearPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA Nov 06 | 2020Novo to Acquire Emisphere Technologies; Mylan Q3 '20 Earnings UpdatePurchase Blast
$599
Posted in: DPP-IVi, Dual/triple agonist, GLP-1RA, SGLT2i Nov 05 | 2020AZ, Provention Bio, Teva, and BD Q3 '20 Earnings UpdatesPurchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Insulin Delivery Nov 05 | 2020Lilly Invests in Early-Stage Glucose-Responsive Insulin Company; Novo Presents Full STEP 3 Results; Lifescan Hires New Head of Marketing; New CymaBay GPR119 Hypo Prevention TrialPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Insulin Delivery Nov 04 | 2020Insulet, Mannkind, and Lannett Q3 '20 Earnings UpdatesPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA Nov 02 | 2020Novo/Gilead NASH PoC Data @ AASLD; Novo Q3 '20 London Earnings EventPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, GLP-1RA + Basal, Other Oct 30 | 2020Novo to use PRV for Sema Obesity; Ph1 Glucose-responsive Insulin Trial Initiated; Novo Q3 '20 Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, SGLT2i Oct 29 | 2020Negative Entresto Adcom Could Renew Interest in Sotagliflozin - Lexicon and Sanofi Q3 '20 Earnings Updates; Lifescan Partners for Diabetes CoachingPurchase Blast
$599
Posted in: Glucose Monitoring, Other Oct 29 | 2020Nemaura Medical Q2 '20 Earnings Update; Cecelia Health Secures $13M in Series B FundingPurchase Blast
$599
Posted in: Glucose Monitoring Oct 28 | 2020Teladoc and Livongo Q3 '20 Earnings UpdatesPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery Oct 27 | 2020Dexcom G7 Reduced Wear Time; Q3 '20 Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucagon, Other, SGLT2i Oct 27 | 2020Lilly, Novartis, Pfizer, and Merck Q3 '20 Earnings UpdatesPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
